NASDAQ:GCTK Stock Quote
0.2050
-0.0273 (-11.75%)
GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes
The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · March 19, 2025
DETROIT, MICHIGAN - March 19, 2025 ( NEWMEDIAWIRE ) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga’s All-Access.
Via TheNewswire.com · March 19, 2025
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
By Glucotrack, Inc. · Via GlobeNewswire · March 19, 2025

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
By Glucotrack, Inc. · Via GlobeNewswire · February 26, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 25, 2025
By JE Insights, Benzinga
Via TheNewswire.com · February 25, 2025

The study met its primary endpoint with no procedure or device related serious adverse events reported
By Glucotrack, Inc. · Via GlobeNewswire · February 4, 2025

1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025
By Glucotrack, Inc. · Via GlobeNewswire · January 30, 2025

Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 29, 2025

ISO Certification highlights commitment to quality for continuous blood glucose monitor
By Glucotrack, Inc. · Via GlobeNewswire · January 21, 2025

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 15, 2025

Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 7, 2025

VANCOUVER, BC / ACCESSWIRE / July 26, 2023 / The Power Play by The Market Herald has announced the release of new interviews with GlucoTrack and Acceleware discussing their latest news.
Via ACCESSWIRE · July 26, 2023

NEW YORK, NY / ACCESSWIRE / April 17, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ:GCTK).
Via ACCESSWIRE · April 17, 2023

VANCOUVER, BC / ACCESSWIRE / October 27, 2022 / The Power Play by The Market Herald has announced the release of new interviews with NextSource, Good Natured Products, SoLVBL, Geologica and GlucoTrack discussing their latest news.
Via ACCESSWIRE · October 27, 2022

INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM
By GlucoTrack, Inc. · Via GlobeNewswire · October 14, 2022

VANCOUVER, BC / ACCESSWIRE / October 12, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SoLVBL, C3 Metals, Charbone Hydrogen, GlucoTrack and Atomic Minerals discussing their latest news.
Via ACCESSWIRE · October 12, 2022

Rutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
By GlucoTrack, Inc. · Via GlobeNewswire · October 10, 2022